Vesilute vs HGH Fragment 176-191
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
VesiluteFat Loss & Metabolic
HGH Fragment 176-191- Summary
- Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~30 minutes
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 250–500 mcg
- Frequency
- Daily for 10–30 days
- 1–3 times daily
- Key Benefits
- Supports retinal photoreceptor cell function and survival
- May slow progression of age-related macular degeneration
- Reduces retinal cell apoptosis from oxidative stress and aging
- Anti-aging effects on retinal pigment epithelium
- Potential support in diabetic retinopathy management
- Preserves visual acuity with aging
- Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant ocular adverse events reported at standard doses
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- Stacks With
- —
- —